Phase 1/2 Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults (clinicaltrials.gov) - May 13, 2026 - P1/2 | N=612 | Active, not recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty | Recruiting ➔ Active, not recruiting | Phase classification: P1 ➔ P1/2 | N=192 ➔ 612 | Trial completion date: Jun 2026 ➔ Jul 2028 | Trial primary completion date: Mar 2026 ➔ Mar 2028
Enrollment change • Enrollment closed • First-in-human • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
|